Genedrive PLC Notice of Results (1967G)

TIDMGDR

RNS Number : 1967G

Genedrive PLC

14 November 2022

genedrive plc

("genedrive" or the "Company")

Notice of Results

Investor Presentation

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it will release its preliminary results for the year ended 30 June 2022 on Monday, 21 November 2022.

The Company will provide a live presentation to accompany the results, presented by CEO, David Budd and CFO, Russ Shaw on Monday, 21 November 2022 at 12.00pm.

The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and add genedrive plc to meet the Company via the following link: https://www.investormeetcompany.com/genedrive-plc/register-investor

For further details please contact:

 
 genedrive plc                                                                   +44 (0)161 989 0245 
 David Budd: CEO / Russ Shaw: CFO 
 
 Peel Hunt LLP (Nominated Adviser 
  and Joint Broker)                                                              +44 (0)20 7418 8900 
 James Steel 
 Oliver Duckworth 
 
            finnCap (Joint Broker)                                               +44 (0)20 7220 0500 
            Geoff Nash / George Dollemore / Nigel 
             Birks / Alice Lane 
 
 Walbrook PR Ltd (Media & Investor                   +44 (0)20 7933 8780 or genedrive@walbrookpr.com 
  Relations) 
                                                                   +44 (0)7980 541 893 / +44 (0)7876 
 Paul McManus / Anna Dunphy                                                                  741 001

About genedrive plc ( http://www.genedriveplc.com ) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and a test to help in the prevention of hearing loss caused by certain antibiotics in neonates. The Company recently released point of care test for Covid-19.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORBBBITMTIBBPT

(END) Dow Jones Newswires

November 14, 2022 02:00 ET (07:00 GMT)

Genedrive (LSE:GDR)
Historical Stock Chart
From Mar 2024 to Apr 2024